Unknown

Dataset Information

0

Prophylactic Use of Enoxaparin in Adolescents During Bariatric Surgery-a Prospective Clinical Study.


ABSTRACT:

Introduction

Severe obesity predisposes youth to a higher risk of venous thromboembolism (VTE). This study evaluates a BMI-stratified prophylactic dosing regimen of enoxaparin in adolescents with severe obesity undergoing surgery.

Methods

Adolescents aged 12-20 years received prophylactic enoxaparin at 40 mg SC (for a BMI?2) and 60 mg SC (for a BMI???50 kg/m2) every 12 h until discharge. Blood samples were drawn at pre-dose, 1, 2, 4, 6, and 12 h. Plasma Anti-Factor Xa (Anti-FXa) activity was used as a surrogate marker for enoxaparin pharmacokinetics.

Results

Ten female and two male obese adolescents (age range 14-19 years) had a mean BMI of 49.9 kg/m2 (38.4-58 kg/m2). Four patients had a BMI of less than 50 kg/m2 and received 40 mg enoxaparin, resulting in a mean dosage of 0.352?±?0.070 mg/kg body weight. Eight patients were dosed with 60 mg enoxaparin every 12 h, resulting in a mean dosage of 0.395?±?0.028 mg/kg. Peak plasma anti-FXa activity (Cmax) ranged from 0.14 to 0.30 IU/mL, median Cmax was 0.205 IU/mL. Median Tmax was 5.67 h (range 3.78-7.52 h). Median AUCi was 1.00 h IU/mL (range 0.42-1.67 h IU/mL). Ten out of 12 patients (83%) reached the primary endpoint with anti-FXa activity in the range for VTE prevention (0.1-0.3 IU/mL).

Conclusions

Our dosing scheme of 40 mg vs. 60 mg enoxaparin stratified according to BMI proved to be effective in reaching prophylactic anti-FXa activity in 83% of adolescent patients.

SUBMITTER: Vaughns JD 

PROVIDER: S-EPMC7375856 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Prophylactic Use of Enoxaparin in Adolescents During Bariatric Surgery-a Prospective Clinical Study.

Vaughns Janelle D JD   Ziesenitz Victoria C VC   Williams Elaine F EF   Nadler Evan P EP   Mikus Gerd G   van den Anker Johannes J  

Obesity surgery 20200101 1


<h4>Introduction</h4>Severe obesity predisposes youth to a higher risk of venous thromboembolism (VTE). This study evaluates a BMI-stratified prophylactic dosing regimen of enoxaparin in adolescents with severe obesity undergoing surgery.<h4>Methods</h4>Adolescents aged 12-20 years received prophylactic enoxaparin at 40 mg SC (for a BMI < 50 kg/m<sup>2</sup>) and 60 mg SC (for a BMI ≥ 50 kg/m<sup>2</sup>) every 12 h until discharge. Blood samples were drawn at pre-dose, 1, 2, 4, 6, and 12 h. Pla  ...[more]

Similar Datasets

2017-07-21 | GSE66676 | GEO
| S-EPMC6319537 | biostudies-literature
| S-EPMC5861708 | biostudies-literature
| S-EPMC4060250 | biostudies-literature
| PRJEB39382 | ENA
| PRJEB28869 | ENA
| S-EPMC5568472 | biostudies-literature
| S-EPMC7166172 | biostudies-literature
| S-EPMC7027488 | biostudies-literature
| S-EPMC5568488 | biostudies-literature